NASDAQ: INVOInvo Bioscience Inc Stock
$0.98-0.19 (-16.24%)
Updated Apr 25, 2024
INVO Price
$0.98
Fair Value Price
N/A
Market Cap
$2.69M
52 Week Low
$0.50
52 Week High
$10.50
P/E
-0.19x
P/B
3.01x
P/S
0.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.02M
Earnings
-$8.03M
Gross Margin
36%
Operating Margin
-234.42%
Profit Margin
-266%
Debt to Equity
22.4
Operating Cash Flow
-$5M
Beta
1.25
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INVO Overview
INVO Bioscience Incorporated is a commercial-stage company developing tassisted reproductive technologies intended to make fertility care accessible to people around the world. The company's flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place within the woman's body. Its treatment solution is an intravaginal culture technique which incubates both oocytes and sperm during fertilization and early embryo development. INVO Bioscience was founded in 2007 and is headquartered in Sarasota, FL.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INVO is good value based on its book value relative to its share price (3.01x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
INVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INVO due diligence checks available for Premium users.
Be the first to know about important INVO news, forecast changes, insider trades & much more!
INVO News
Valuation
INVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
29.73x
Market
40.97x
INVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.01x
Industry
3.71x
INVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INVO's financial health
Profit margin
Revenue
$1.4M
Net Income
-$2.0M
Profit Margin
-144.4%
INVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.9M
Liabilities
$20.0M
Debt to equity
22.4
INVO's short-term liabilities ($8.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVO's long-term liabilities ($11.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$714.9k
Investing
$33.3k
Financing
-$141.5k
INVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INVO vs Medical Device Stocks
Invo Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.